Dr Barry Hock

2026

Journal - Research Article

Dobson, L. J., Hock, B. D., Drabble, A. H. T., Goddard, L., McKenzie, J. L., MacPherson, S. A., & McLellan, A. D. (2026). Enhanced Fc and complement activity of Fc-modified avelumab boosts anti-tumor activity but promotes NK cell fratricide. Clinical & Translational Immunology, 15, e70098. doi: 10.1002/cti2.70098

2025

Journal - Research Article

Hock, B. D., Goddard, L., Dobson, L. J., MacPherson, S. A., O'Donnell, J. L., McKenzie, J. L., & McLellan, A. D. (2025). Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1/PD-L1. Cancer Immunology, Immunotherapy, 74, 216. doi: 10.1007/s00262-025-04078-0

2024

Journal - Research Article

Permain, J., Hock, B., Eglinton, T., & Purcell, R. (2024). Functional links between the microbiome and the molecular pathways of colorectal carcinogenesis. Cancer & Metastasis Reviews, 43, 1463-1474. doi: 10.1007/s10555-024-10215-5

Keating, P. E., Hock, B. D., Chin, P. K. L., O'Donnell, J. L., & Barclay, M. L. (2024). Evaluation of the homogenous mobility shift assay for infliximab and adalimumab anti-drug antibody detection in the clinical laboratory. Therapeutic Drug Monitoring, 46(5), 619-626. doi: 10.1097/ftd.0000000000001200

Journal - Research Other

Topham, B., Hock, B., Phillips, E., Wiggins, G., & Currie, M. (2024). The role of innate priming in modifying tumor-associated macrophage phenotype. Frontiers in Bioscience - Landmark, 29(12), 418. doi: 10.31083/j.fbl2912418

2023

Journal - Research Article

Hock, B. D., Goddard, L., MacPherson, S. A., Strother, M., Gibbs, D., Pearson, J. F., & McKenzie, J. L. (2023). Levels and in vitro functional effects of circulating anti-hinge antibodies in melanoma patients receiving the immune checkpoint inhibitor pembrolizumab. PLoS ONE, 18(9), e0290793. doi: 10.1371/journal.pone.0290793

Sulit, A. K., Daigneault, M., Allen-Vercoe, E., Silander, O. K., Hock, B., McKenzie, J., Pearson, J., Frizelle, F. A., Schmeier, S., & Purcell, R. (2023). Bacterial lipopolysaccharide modulates immune response in the colorectal tumor microenvironment. npj Biofilms & Microbiomes, 9, 59. doi: 10.1038/s41522-023-00429-w

Keenan, J. I., Aitchison, A., Frizelle, F. A., & Hock, B. D. (2023). Detection of chitinase 3-like 1 in symptomatic primary care patient faecal samples is not a reliable biomarker of colonic lesions. Asian Pacific Journal of Cancer Prevention, 24(7), 2289-2293. doi: 10.31557/APJCP.2023.24.7.2289

Journal - Research Other

Keating, P. E., Hock, B. D., Smith, S. M., Chin, P. K. L., O'Donnell, J. L., & Barclay, M. L. (2023). Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing [Brief communication]. Internal Medicine Journal, 53(11), 2123-2127. doi: 10.1111/imj.16264

Conference Contribution - Published proceedings: Abstract

Barclay, M. L., Keating, P. E., Hock, B. D., Chin, P. K. L., & O'Donnell, J. L. (2023). Infliximab or adalimumab antidrug-antibody complex size has more clinical value than concentration. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. 235. Retrieved from https://www.asceptasm.com

Barclay, M. L., Keating, P. E., Hock, B. D., Smith, S. M., Chin, P. K. L., & O'Donnell, J. L. (2023). Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating high potential for improved dosing. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. P513. Retrieved from https://www.asceptasm.com

2022

Journal - Research Article

Ghodsian, N., Yeandle, A., Hock, B. D., & Gieseg, S. P. (2022). CD36 down regulation by the macrophage antioxidant 7,8-dihydroneopterin through modulation of PPAR-γ activity. Free Radical Research, 56(5-6), 366-377. doi: 10.1080/10715762.2022.2114904

Conference Contribution - Published proceedings: Abstract

Sulit, A., Daigneault, M., Allen-Vercoe, E., Silander, O., Hock, B., McKenzie, J., Pearson, J., Frizelle, F., … Purcell, R. (2022). Lipopolysaccharide from colorectal cancer-associated bacteria influence cytokine production in immune cells. Colorectal Disease, 24(Suppl. 1), (pp. 55-56). doi: 10.1111/codi.16048

Permain, J., Purcell, R., Sulit, A., Hock, B., & Eglinton, T. (2022). Novel functional links between colorectal carcinogenesis and the microbiome. Colorectal Disease, 24(Suppl. 1), (pp. 4-5). doi: 10.1111/codi.16048

2021

Journal - Research Article

Buss, L. A., Hock, B., Merry, T. L., Ang, A. D., Robinson, B. A., Currie, M. J., & Dachs, G. U. (2021). Effect of immune modulation on the skeletal muscle mitochondrial exercise response: An exploratory study in mice with cancer. PLoS ONE, 16(10), e0258831. doi: 10.1371/journal.pone.0258831

Buss, L. A., Williams, T., Hock, B., Ang, A. D., Robinson, B. A., Currie, M. J., & Dachs, G. U. (2021). Effects of exercise and anti-PD-1 on the tumour microenvironment. Immunology Letters, 239, 60-71. doi: 10.1016/j.imlet.2021.08.005

Journal - Research Other

Keating, P. E., O'Donnell, J. L., & Hock, B. D. (2021). Accurate measurement of adalimumab using competitive homogenous mobility shift assay. Therapeutic Drug Monitoring, 43(1), 140-141. doi: 10.1097/FTD.0000000000000822

Buss, L. A., Dachs, G. U., Goddard, L., Ang, A. D., Robinson, B. A., Currie, M. J., & Hock, B. (2021). Is the immunogenicity of PD-1 blocking antibodies a confounding variable in murine studies? Immunology Letters, 234, 13-15. doi: 10.1016/j.imlet.2021.04.003

Conference Contribution - Published proceedings: Abstract

Gieseg, S. P., Baxter-Parker, G., Cross, S., Hock, B., & Cousins, A. (2021). Neopterin formation through radical scavenging of superoxide by the macrophage synthesised antioxidant 7,8-dihydroneopterin: Clinical implications. Proceedings of the 16th Congress of the Federation of Asian & Oceanic Biochemists & Molecular Biologists (FAOBMB). (pp. 279). Retrieved from https://www.faobmb2021.org

2020

Journal - Research Article

Hock, B. D., McKenzie, J. L., Strother, M., Goddard, L., Butt, L., & Currie, M. J. (2020). Functional effects of immune complexes formed between pembrolizumab and patient-generated anti-drug antibodies. Cancer Immunology, Immunotherapy, 69(12), 2453-2464. doi: 10.1007/s00262-020-02636-2

Buss, L. A., Ang, A. D., Hock, B., Robinson, B. A., Currie, M. J., & Dachs, G. U. (2020). Effect of post-implant exercise on tumour growth rate, perfusion and hypoxia in mice. PLoS ONE, 15(3), e0229290. doi: 10.1371/journal.pone.0229290

Baxter-Parker, G., Prebble, H. M., Cross, S., Steyn, N., Shchepetkina, A., Hock, B. D., … Gieseg, S. P. (2020). Neopterin formation through radical scavenging of superoxide by the macrophage synthesised antioxidant 7,8-dihydroneopterin. Free Radical Biology & Medicine, 152, 142-151. doi: 10.1016/j.freeradbiomed.2020.03.002

Journal - Research Other

Keating, P. E., Duncan, R., Spellerberg, M., O'Donnell, J., & Hock, B. D. (2020). Measurement of anti-natalizumab antibodies by homogeneous mobility shift assay. Pathology, 52(3), 373-374. doi: 10.1016/j.pathol.2020.01.682

2019

Journal - Research Article

Hock, B. D., Smith, S. M., McEntyre, C. J., McKenzie, J. L., Sies, C., & Keating, P. E. (2019). Development of a competitive binding homogeneous mobility shift assay for the quantification of adalimumab levels in patient serum. Journal of Immunological Methods, 474, 112672. doi: 10.1016/j.jim.2019.112672

Hock, B. D., Mulholland, K. S., Ganly, P., McKenzie, J. L., Pearson, J. F., & MacPherson, S. A. (2019). Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre. Internal Medicine Journal, 49, 598-606. doi: 10.1111/imj.14155

Barclay, M. L., Karim, S., Helms, E. T. J., Keating, P. E., Hock, B., Stamp, L. K., & Schultz, M. (2019). Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays. Internal Medicine Journal, 49, 513-518. doi: 10.1111/imj.14064

Journal - Research Other

Purcell, R. V., Hock, B. D., Gardner, J., Goddard, L., MacPherson, S. A., & McKenzie, J. L. (2019). Analysis of human papillomavirus infection and leukaemic infiltrate in cutaneous squamous cell carcinoma from patients with chronic lymphocytic leukaemia. British Journal of Haematology, 186(4), e67-e71. doi: 10.1111/bjh.15907

2018

Journal - Research Article

Hock, B. D., McKenzie, J. L., Goddard, L., Smith, S. M., McEntyre, C. J., & Keating, P. E. (2018). Discrimination of anti-drug antibodies with neutralizing capacity in infliximab-and adalimumab-treated patients: Comparison of the homogeneous mobility shift assay and the affinity capture and elution assay. Therapeutic Drug Monitoring, 40(6), 705-715. doi: 10.1097/FTD.0000000000000553

Prebble, H., Cross, S., Marks, E., Healy, J. L., Searle, E., Aamir, R., Butler, A., Roake, J., Hock, B., Anderson, N., & Gieseg, S. P. (2018). Induced macrophage activation in live excised atherosclerotic plaque. Immunobiology, 223(8-9), 526-535. doi: 10.1016/j.imbio.2018.03.002

Conference Contribution - Published proceedings: Abstract

Buss, L., Currie, M., Ang, A., Hock, B., & Dachs, G. (2018). Exercise reduces hypoxia and increases perfusion in tumours from mice with melanoma. Proceedings of the New Zealand Society for Oncology (NZSO) Conference. Retrieved from http://www.nzsoncology.org.nz/

Gieseg, S. P., Prebble, H., Cross, S., & Hock, B. (2018). The macrophage inflammation marker neopterin is generated by the reaction with superoxide released during oxLDL mediated cell death. Atherosclerosis Supplements, 32, (pp. 124). doi: 10.1016/j.atherosclerosissup.2018.04.380

Conference Contribution - Poster Presentation (not in published proceedings)

Buss, L., Currie, M., Ang, A., Hock, B., & Dachs, G. (2018, August). Post-tumour-implantation exercise does not alter tumour growth rate in mice with subcutaneous B16-F10 melanoma. Poster session presented at the Queenstown Molecular Biology (QMB) Meetings, Queenstown, New Zealand.

Conference Contribution - Verbal presentation and other Conference outputs

Buss, L., Currie, M., Ang, A., Hock, B., & Dachs, G. (2018, August). T-cell distribution in melanoma from exercising mice. Verbal presentation at the Queenstown Molecular Biology (QMB) and Australasian Society for Immunology New Zealand Branch (ASI-NZ) Joint Meeting, Queenstown, New Zealand.

2017

Journal - Research Article

Shchepetkina, A. A., Hock, B. D., Miller, A., Kennedy, M. A., & Gieseg, S. P. (2017). Effect of 7,8-dihydroneopterin mediated CD36 down regulation and oxidant scavenging on oxidised low-density lipoprotein induced cell death in human macrophages. International Journal of Biochemistry & Cell Biology, 87, 27-33. doi: 10.1016/j.biocel.2017.03.017

Hock, B. D., MacPherson, S. A., & McKenzie, J. L. (2017). Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells. PLoS ONE, 12(3), e0172858. doi: 10.1371/journal.pone.0172858

Journal - Research Other

Hock, B. D., McKenzie, J. L., & Keenan, J. I. (2017). Helicobacter pylori outer membrane vesicles inhibit human T cell responses via induction of monocyte COX-2 expression [Short communication]. Pathogens & Disease, 75(4), ftx034. doi: 10.1093/femspd/ftx034

Conference Contribution - Published proceedings: Abstract

O'Donnell, J., Liu, J., Keating, P., Hock, B., Spellerberg, M., Barclay, M., & Stamp, L. (2017). Anti-drug antibodies (ADA): Assay performance in patients treated for inflammatory bowel and rheumatic disease with biodrugs, adalimumab and infliximab. Internal Medicine Journal, 47(Suppl. 2), (pp. 15). doi: 10.1111/imj.13426

Conference Contribution - Verbal presentation and other Conference outputs

Currie, M., Hock, B., McKenzie, J., Miller, A., Simcock, J., Mackenzie, K., Seddon, A., & Kennedy, B. (2017, July). Functional and prognostic significance of neutrophil subpopulations in cutaneous squamous cell carcinoma. Verbal presentation at the New Zealand Branch of the Australasian Society for Immunology (NZ ASI) Annual Scientific Meeting, Christchurch, New Zealand.

2016

Journal - Research Article

Hock, B. D., McIntosh, N. D., McKenzie, J. L., Pearson, J. F., Simcock, J. W., & MacPherson, S. A. (2016). Incidence of cutaneous squamous cell carcinoma in a New Zealand population of chronic lymphocytic leukaemia patients. Internal Medicine Journal, 46(12), 1414-1421. doi: 10.1111/imj.13261

Seddon, A., Hock, B., Miller, A., Frei, L., Pearson, J., McKenzie, J., Simcock, J., & Currie, M. (2016). Cutaneous squamous cell carcinomas with markers of increased metastatic risk are associated with elevated numbers of neutrophils and/or granulocytic myeloid derived suppressor cells. Journal of Dermatological Science, 83(2), 124-130. doi: 10.1016/j.jdermsci.2016.04.013

Hock, B. D., Stamp, L. K., Hayman, M. W., Keating, P. E., Helms, E. T. J., & Barclay, M. L. (2016). Development of an ELISA-based competitive binding assay for the analysis of drug concentration and anti-drug antibody levels in patients receiving adalimumab or infliximab. Therapeutic Drug Monitoring, 38(1), 32-41. doi: 10.1097/ftd.0000000000000229

Conference Contribution - Published proceedings: Abstract

Keating, P., Hock, B., Barclay, M., Stamp, L., Spellerberg, M., & O'Donnell, J. (2016). Application of an ELISA based competitive binding assay to measure concentration of anti-TNF biologics and neutralising anti-drug antibodies in the clinical laboratory. European Journal of Immunology, 46(Suppl. 1), (pp. 1033). doi: 10.1002/eji.201670200

Keating, P., Zhang, M., & Hock, B. D. (2016). Measurement of anti-TNF biologics and anti-drug antibodies in the clinical laboratory. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting. (pp. 22). Retrieved from http://www.queenstownresearchweek.org/index.php/ascept-nz/

2015

Journal - Research Article

Hock, B. D., McKenzie, J. L., Cross, N. B., & Currie, M. J. (2015). Dynamic changes in myeloid derived suppressor cell subsets following renal transplant: A prospective study. Transplant Immunology, 32(3), 164-171. doi: 10.1016/j.trim.2015.05.001

Conference Contribution - Published proceedings: Abstract

Seddon, A. R., Hock, B. D., Miller, A. P., Frei, L. P., Pearson, J. F., McKenzie, J. L., Simcock, J. W., & Currie, M. J. (2015). Neutrophils in cutaneous squamous cell carcinoma: Potential prognostic markers? New Zealand Medical Journal, 128(1421). Retrieved from https://www.nzma.org.nz/journal

Conference Contribution - Poster Presentation (not in published proceedings)

Hock, B. D., McKenzie, J. L., & Keenan, J. I. (2015, November). Helicobacter pylori outer membrane vesicles modulate human immune responses. Poster session presented at the 18th International Conference on Campylobacter, Helicobacter, and Related Organisms (CHRO), Rotorua, New Zealand.

2014

Journal - Research Article

Hock, B. D., MacPherson, S. A., Fernyhough, L. J., & McKenzie, J. L. (2014). Chronic lymphocytic leukemia cells become both activated and immunosuppressive following interaction with CD3 and CD28 stimulated PBMC. Leukemia Research, 38(10), 1217-1223. doi: 10.1016/j.leukres.2014.06.004

Conference Contribution - Published proceedings: Abstract

Barclay, M. L., Helms, E., Hock, B., Schultz, M., & Stamp, L. K. (2014). Trough concentrations of infliximab and adalimumab, and anti-drug antibodies, correlate with drug response in inflammatory bowel disease. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Molecular Pharmacology of G Protein-Coupled Receptors (MPGPCR) Joint Scientific Meeting. (pp. 25). Retrieved from http://www.asceptasm.com/

Frei, L. P., Hock, B., & Simcock, J. (2014). High neutrophil count is associated with increased severity of cutaneous squamous cell carcinoma. ANZ Journal of Surgery, 84(Suppl. 1), (pp. 155). doi: 10.1111/ans.12623

Conference Contribution - Verbal presentation and other Conference outputs

Barclay, M. L., Helms, E., Hock, B., Stamp, L. K., & Schultz, M. (2014, November). Infliximab and adalimumab trough concentrations and anti-drug antibodies correlate with response in inflammatory bowel disease. Verbal presentation at the New Zealand Society of Gastroenterology & New Zealand Nurses Organisation Gastroenterology Section Annual Scientific Meeting, Auckland, New Zealand.

2013

Journal - Research Article

Hock, B. D., Fernyhough, L. J., Gough, S. M., & McKenzie, J. L. (2013). Clinical significance of plasma levels of soluble CD40 in patients with chronic lymphocytic leukemia. Open Journal of Blood Diseases, 3(1), 1-5. doi: 10.4236/ojbd.2013.31001

Fernyhough, L. J., Hock, B. D., Taylor, J., Pearson, J., & Ganly, P. (2013). Survival of myeloma patients following the introduction of thalidomide as a second-line therapy: A retrospective study at a single New Zealand centre. Internal Medicine Journal, 43(2), 130-137. doi: 10.1111/j.1445-5994.2012.02819.x

Fernyhough, L. J., Buchan, V. A., McArthur, L. T., & Hock, B. D. (2013). Relative recovery of haematopoietic stem cell products after cryogenic storage of up to 19 years. Bone Marrow Transplantation, 48(1), 32-35. doi: 10.1038/bmt.2012.97

Journal - Research Other

Hock, B. D., & McKenzie, J. L. (2013). Suppression of CD3/CD28 antibody stimulated responses by human granulocytic myeloid-derived suppressor cells: Fact or artefact? Immunology Letters, 152(2), 151-152. doi: 10.1016/j.imlet.2013.05.009

2012

Journal - Research Article

Hock, B. D., Taylor, K. G., Cross, N. B., Kettle, A. J., Hampton, M. B., & McKenzie, J. L. (2012). Effect of activated human polymorphonuclear leucocytes on T lymphocyte proliferation and viability. Immunology, 137(3), 249-258. doi: 10.1111/imm.12004

Hock, B. D., Mackenzie, K. A., Cross, N. B., Taylor, K. G., Currie, M. J., Robinson, B. A., Simcock, J. W., & McKenzie, J. L. (2012). Renal transplant recipients have elevated frequencies of circulating myeloid-derived suppressor cells. Nephrology Dialysis Transplantation, 27(1), 402-410. doi: 10.1093/ndt/gfr264

2011

Journal - Research Article

MacKenzie, K. A., Miller, A. P., Hock, B. D., Gardner, J., Simcock, J. W., Roake, J. A., Dachs, G. U., Robinson, B. A., & Currie, M. J. (2011). Angiogenesis and host immune response contribute to the aggressive character of non-melanoma skin cancers in renal transplant recipients. Histopathology, 58(6), 875-885. doi: 10.1111/j.1365-2559.2011.03845.x

Geertsema, L., Lucas, S. J. E., Cotter, J. D., Hock, B., McKenzie, J., & Fernyhough, L. J. (2011). The cardiovascular risk factor, soluble CD40 ligand (CD154), but not soluble CD40, is lowered by ultra-endurance exercise in athletes. British Journal of Sports Medicine, 45(1), 42-45. doi: 10.1136/bjsm.2008.051896

Conference Contribution - Published proceedings: Abstract

Taylor, J., Fernyhough, L., Hock, B., & Ganly, P. (2011). Multiple myeloma patients treated in Christchurch, New Zealand: A retrospective analysis. Proceedings of the Inaugural International Cancer Symposium. Retrieved from http://www.wnmeds.ac.nz/cancersymposium/programme.html

2010

Journal - Research Article

Hock, B. D., McKenzie, J. L., McArthur, L., Tansley, S., Taylor, K. G., & Fernyhough, L. J. (2010). CD38 as a prognostic marker in chronic lymphocytic leukaemia at a single New Zealand centre: Patient survival in comparison to age and sex matched population data. Internal Medicine Journal, 40(12), 842-849. doi: 10.1111/j.1445-5994.2009.02135.x

2009

Journal - Research Article

Hock, B. D., Fernyhough, L. J., Gough, S. M., Steinkasserer, A., Cox, A. G., & McKenzie, J. L. (2009). Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia. Leukemia Research, 33(8), 1089-1095. doi: 10.1016/j.leukres.2009.01.001

Conference Contribution - Verbal presentation and other Conference outputs

Saunderson, S. C., Schuberth, P., Dunn, A. C., Miller, L., Hock, B. D., MacKay, P. A., … Jack, R. W., & McLellan, A. D. (2009, June). Primary B cell derived exosomes bind the marginal zone of the spleen. Verbal presentation at the New Zealand Australasian Society for Immunology (NZ ASI) Branch Meeting, Wellington, New Zealand.

2008

Journal - Research Article

Saunderson, S. C., Schuberth, P. C., Dunn, A. C., Miller, L., Hock, B. D., MacKay, P. A., … Jack, R. W., & McLellan, A. D. (2008). Induction of exosome release in primary B cells stimulated via CD40 and the IL-4 receptor. Journal of Immunology, 180(12), 8146-8152.

Conference Contribution - Poster Presentation (not in published proceedings)

Saunderson, S. C., Schuberth, P. C., Dunn, A. C., Miller, L., Hock, B. D., MacKay, P. A., … Jack, R. W., & McLellan, A. D. (2008, November). Induction of exosome release in primary B cells stimulated via CD40 and the IL-4 receptor. Poster session presented at the Medical Sciences Congress, Queenstown, New Zealand.

2006

Journal - Research Article

Hock, B. D., McKenzie, J. L., Patton, N. W., Drayson, M., Taylor, K., Wakeman, C., … Albitar, M. (2006). Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer, 106(10), 2148-2157.

Hock, B. D., Drayson, M., Patton, W. N., Taylor, K., Kerr, L., McKenzie, J. L., & on behalf of the Working Party on Leukaemia in Adults. (2006). Circulating levels and clinical significance of soluble CD86 in myeloma patients. British Journal of Haematology, 133, 165-172.

Hock, B. D., O'Donnell, J. L., Taylor, K., Steinkasserer, A., McKenzie, J. L., Rothwell, A. G., & Summers, K. L. (2006). Levels of the soluble forms of CD80, CD86, and CD83 are elevated in the synovial fluid of rheumatoid arthritis patients. Tissue Antigens, 67(1), 57-60. doi: 10.1111/j.1399-0039.2005.00524.x

Zinser, E., Lechmann, M., Golka, A., Hock, B., & Steinkasserer, A. (2006). Determination of the inhibitory activity and biological half-live of soluble CD83: Comparison of wild type and mutant isoforms. Immunobiology, 211, 449-453.

2005

Journal - Research Article

Hock, B. D., Roberts, G., McKenzie, J. L., Gokhale, P., Salm, N., McLellan, A. D., Patton, N. W., & Roake, J. A. (2005). Exposure to the electrofusion process can increase the immunogenicity of human cells. Cancer Immunology, Immunotherapy, 54, 880-890.

Conference Contribution - Verbal presentation and other Conference outputs

Keenan, J., Peterson, R., Ismail, S., Hock, B., Frampton, C., & Hampton, M. (2005, September). Host iron deficiency alters the outcome of infection in Helicobacter pylori-infected mice. Verbal presentation at the 13th International Workshop on Campylobacter, Helicobacter and Related Organisms, Gold Coast, Australia.

2004

Journal - Research Article

Hock, B. D., Starling, G. C., Patton, W. N., Salm, N., Bond, K., McArthur, L. T., & McKenzie, J. L. (2004). Identification of a circulating soluble form of CD80: Levels in patients with hematological malignancies. Leukemia & Lymphoma, 45(10), 2111-2118. doi: 10.1080/10428190410001712199

Hock, B. D., Haring, L. F., Steinkasserer, A., Taylor, K. G., Patton, W. N., & McKenzie, J. L. (2004). The soluble form of CD83 is present at elevated levels in a number of hematological malignancies. Leukemia Research, 28, 237-241.

2003

Journal - Research Article

Hock, B. D., McKenzie, J., Patton, W. N., Haring, L., Yang, Y., Shen, Y., … Albitar, M. (2003). The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer, 98, 1681-1688.

2001

Journal - Research Article

Summers, K. L., Hock, B. D., McKenzie, J. L., & Hart, D. N. J. (2001). Phenotypic characterization of five dendritic cell subsets in human tonsils. American Journal of Pathology, 159, 285-295.

Hock, B. D., Kato, M., McKenzie, J., & Hart, D. N. J. (2001). A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera. International Immunology, 13(7), 959-967.

2000

Journal - Research Article

El Sherbini, H., Hock, B., Fearnley, D., McLellan, A., Vuckovic, S., & Hart, D. N. J. (2000). Lectin ligands on human dendritic cells and identification of a peanut agglutinin positive subset in blood. Cellular Immunology, 200, 36-44. doi: 10.1006/cimm.1999.1612

1999

Journal - Research Article

Hock, B. D., Fearnley, D. B., Boyce, A., McLellan, A. D., Sorg, R. V., Summers, K., & Hart, D. N. J. (1999). Human dendritic cells express a 95 kDa activation/differentiation antigen defined by CMRF-56. Tissue Antigens, 53(4), 320-334. doi: 10.1034/j.1399-0039.1999.530402.x

1998

Journal - Research Article

Sorg, R. V., McLellan, A. D., Hock, B. D., Fearnley, D. B., & Hart, D. N. J. (1998). Human dendritic cells express functional interleukin-7. Immunobiology, 198(5), 514-526. doi: 10.1016/S0171-2985(98)80075-2

1997

Journal - Research Article

Fearnley, D. B., McLellan, A. D., Mannering, S. I., Hock, B. D., & Hart, D. N. J. (1997). Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody: implications for studies on antigen-presenting cell function and immunotherapy. Blood, 89(10), 3708-3726.

Sorg, U. R., Morse, T. M., Patton, W. N., Hock, B. D., Angus, H. B., Robinson, B. A., Colls, B. M., & Hart, D. N. J. (1997). Hodgkin's cells express CD83, a dendritic cell lineage associated antigen. Pathology, 29(3), 294-299. doi: 10.1080/00313029700169125

Conference Contribution - Published proceedings: Full paper

Hart, D. N., Clark, G., Dekker, J. W., Fearnley, D. B., Kato, M., Hock, B. D., McLellan, A. D., Neil, T. K., Sorg, R. V., Sorg, U. R., Summers, K., & Vuckovic, S. (1997). Dendritic cell surface molecules. A proliferating field. Advances in Experimental and Medical Biology. 417, (pp. 439-442). [Full Paper]

McLellan, A. D., Sorg, R. V., Fearnley, D. B., Hock, B. D., Tiedemann, R. J., Fraser, J. R., & Hart, D. N. J. (1997). T lymphocyte mediated regulation of costimulator molecule expression of human dendritic cells. Advances in Experimental and Medical Biology. 417, (pp. 203-206). [Full Paper]

1996

Journal - Research Article

Williams, L. A., Hock, B. D., & Hart, D. N. J. (1996). Human T lymphocytes and hematopoietic cell lines expression CD24-associated carbohydrate epitopes in the absence of CD24 mRNA or protein. Blood, 88(8), 3048-3055.